Antengene’s Xpovio Receives Marketing Approval in Indonesia
China-based biopharma Antengene Corp., Ltd (HKG: 6996) announced receiving marketing approval in Indonesia for its...
China-based biopharma Antengene Corp., Ltd (HKG: 6996) announced receiving marketing approval in Indonesia for its...
China-based biopharma Antengene Corp., Ltd (HKG: 6996) announced that its Xpovio (selinexor), the world’s first...
China-based Antengene Corporation Limited (Antengene, HKG: 6996) announced the presentation of the latest results from...
Antengene Corp., Ltd (HKG: 6996), a biopharmaceutical company based in China, has announced that it...
Antengene Corp., Ltd (HKG: 6996), a biopharmaceutical company based in China, has announced that it...
Antengene Corp., Ltd. (HKG: 6996), a biopharmaceutical company based in China, has announced that it...
Bristol Myers Squibb (BMS; NYSE: BMY) has entered into a collaboration and supply agreement with...
China-based biopharma Antengene Corp., Ltd (HKG: 6996) has announced receiving fast-track designation from the US...
China-based biopharmaceutical company Antengene Corp., Ltd (HKG: 6996) has announced receiving New Drug Application (NDA)...
China-based biotech Antengene Corp., Ltd (HKG: 6996) has revealed that Australia’s Pharmaceutical Benefits Scheme (PBS)...
Antengene Corp., Ltd (HKG: 6996) has announced a market approval filing in Indonesia for its...